(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...

Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...

Eli Lilly is set to report Q3 earnings Wednesday, as the pharma giant continues to gain market share in the weight loss drug space.

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

Highlights,Eli Lilly reported third-quarter profits that fell short of Wall Street estimates, primarily due to higher ...

Eli Lilly shares sank 10% Wednesday morning after its third-quarter results came in well below what analysts were expecting.

Eli Lilly (NYSE: LLY) shares plunged around 10% in premarket trading on Wednesday after it reported third-quarter earnings that fell short of analyst expectations ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

【礼来第三季度销售不及预期 因减肥药销售令人失望】财联社10月30日电，礼来公司 该公司周三下调了全年业绩指引，此前其重磅新药减肥药的销售未达到预期，该公司将其归咎于库存问题。礼来在声明中表示，Zepbound本季度销售额为12.6亿美元，低于分析师平均预期的16.3亿美元。

Shares of Eli Lilly and Co. LLY tumbled 9.6% in premarket trading Wednesday, after the drug maker reported third-quarter profit and revenue that missed expectations by wide margins, as sales of ...

Shares are up more than 50% already this year, as the story surrounding the company’s GLP-1 drugs gets better and better.

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...